Autoimmunity: An underlying factor in the pathogenesis of hypertension

Current Hypertension Reports

Volumn 16, Issue 4, 2014, Pages

  Mathis, Keisa W ^a   Broome, Hanna J ^a   Ryan, Michael J ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Autoantibodies; Autoimmunity; B cells; Blood pressure; Immune system; Inflammation; Lupus; SLE; Systemic lupus erythematosus; T cells

Indexed keywords

AUTOIMMUNITY; BLOOD PRESSURE REGULATION; DISEASE MODEL; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNE SYSTEM; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY;

AUTOANTIBODY; AUTOANTIGEN;

ANIMALS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; HYPERTENSION;

EID: 84893776603     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0424-1     Document Type: Review

References (86)

1. Strickler C. Significance of hypertension. South Med J. 1917;10:191-4.
2. Freis ED. Chapter 164. In: Laragh JH, Brenner BM (eds). Hypertension, Pathophysiology Diagnosis and Management, 2nd ed. New York, Raven Press; 1995 pp 2741-2751.
3. Staessen J, Wang J, Bianchi G, Birkenhager W. Essential hypertension. Lancet. 2003;361:1629-41. (Pubitemid 36579003)
4. Chobanian A. Shattuck lecture: the hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878-87.
5. Lloyd-Jones D, Adams R, Brown T, Carnethon M, Dai S, De S, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121(e46):e215.
6. White F, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964;1:93-102.
7. Svendsen U. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand A. 1976;84:523-8.
8. • Khraibi A, Norman R, Dzielak DJ. Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 1984;247(16):722-6. This study suggested a role for autoimmunity in an experimental model of hypertension. The major finding was that cyclophosphamide effectively reduced blood pressure in spontaneously hypertensive rats.
9. • Dzielak DJ. Immune mechanisms in experimental and essential hypertension. Am J Physiol Regul Integr Comp Physiol. 1991;260(29):459-67. This report is an editorial review which highlights the research that had been done at that time regarding the link between hypertension and immune system activation.
10. Bautista L, Vera L, Arenas I, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149-54. (Pubitemid 40220638)
11. Chae C, Lee R, Rifai N, Ridker P. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399-403. (Pubitemid 34225673)
12. .•• Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449-60. This paper is a seminal study demonstrating that T cells, and not B cells, are involved in the development of angiotensin II mediated hypertension. (Pubitemid 47529329)
13. Ferreri N, Zhao Y, Takizawa H, McGiff J. Tumor necrosis factor-alpha-angiotensin interactions and regulation of blood pressure. J Hypertens. 1997;15:1481-4. (Pubitemid 28039577)
14. Tran L, MacLeod K, McNeill J. Chronic etanercept treatment prevents the development of hypertension in fructose-fed rats. Mol Cell Biochem. 2009;330:219-28.
15. Elmarakby A, Quigley J, Imig J, Pollock J, Pollock D. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008;294:76-83.
16. Elmarakby A, Quigley J, Pollock D, Imig J. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. Hypertension. 2006;47:557-62. (Pubitemid 43843875)
17. Lee D, Sturgis L, Labazi H, Osborne J, Fleming C, Pollock J, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:935-40.
18. • Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500-7. This study was one of the first to establish a role of IL-17 in the development of hypertension.
19. Dhillion P, Wallace K, Herse F, Scott J, Wallukat G, Heath J, et al. IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2012;303(4):353-8.
20. Cornelius D, Hogg J, Scott J, Wallace K, Herse F, Moseley J, et al. Administration of interleukin-17 soluble receptor C suppresses Th17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy. Hypertension. 2013;62(6):1068-73.
21. Nguyen H, Chiasson V, Chatterjee P, Kopriva S, Young K, Mitchell B. Interleukin-17 causes rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013;97(4):696-704.
22. •• Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17:218-25. This is an important study demonstrating that immunosuppressive therapy can reduce blood pressure in hypertensive patients with underlying autoimmune disorders.
23. Ferro C, Edwards N, Hutchison C, Cockwell P, Steeds R, Savage C, et al. Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. Hypertens Res. 2011;34(1):113-9.
24. Muller DN, Shagdarsuren E, Park J-K, Dechend R, Mervaala E, Hampich F, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002;161(5):1679-93. (Pubitemid 35265527)
25. Rodriguez-Iturbe B, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int. 2001;59:2222-32. (Pubitemid 32467615)
26. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl saltsensitive rat. Hypertension. 2006;48:149-56. (Pubitemid 44297537)
27. Miguel C, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2010;298:1136-42.
28. Quiroz Y, Pons H, Gordon K, Rincon J, Chavez M, Parra G, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Ren Physiol. 2001;281:38-47.
29. Tian N, Gu J, Jordan S, Rose R, Hughson M, Manning R. Immune suppresion prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;292:1018-25.
30. De M, Das S, Lund H, Mattson D. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2010;298:1136-42.
31. Boesen E, Williams D, Pollock J, Pollock D. Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxy-corticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol. 2010;37:1016-22.
32. Rodriguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera-Acosta J, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Ren Physiol. 2002;282:191-201.
33. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri N. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol. 2004;24:587-94. (Pubitemid 40187016)
34. Ardiles L, Ehrenfeld P, Quiroz Y, Rodriguez-Iturbe, Herrera-Acosta J, Mezzano S, et al. Effect of mycophenolate mofetil on kallikrein expression in the kidney of 5/6 nephrectomized rats. Kidney Blood Press Res. 2002;25:289-95. (Pubitemid 35356749)
35. Bravo J, Quiroz Y, Pons H, Parra G, Herrera-Acosta J, Johnson RJ, et al. Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition. Kidney Int Suppl. 2003;64:S46-51. (Pubitemid 37159627)
36. Pechman K, Basile D, Lund H, Mattson DL. Immune suppression blocks sodium-sensitive hypertension following recovery from ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol. 2008;294:1234-9.
37. Crowley S, Song Y-S, Lin EE, Griffiths R, Kim H-S, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298:1089-97.
38. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest. 2009;119(4):943-53.
39. Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, et al. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Ren Physiol. 2008;295:515-24.
40. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, et al. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2009;296:208-16.
41. Barhoumi T, Kasal D, Li M, Shbat L, Laurant P, Neves M, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-76.
42. Youn J, Yu H, Lim B, Koh M, Lee J, Chang D, et al. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62(1):126-33.
43. Harrison D, Guzik T, Lob HE, Madhur MS, Marvar P, Thabet S, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-40.
44. Rodriguez-Iturbe B, Franco M, Tapia E, Quiroz Y, Johnson R. Renal inflammation, autoimmunity and salt-sensitive hypertension. Clin Exp Pharmacol Physiol. 2012;39:96-103.
45. Quiroz Y, Johnson R, Rodiguez-Iturbe B. The role of T cells in the pathogenesis of primary hypertension. Nephrol Dial Transplant. 2012;27(S4):iv2-5.
46. Panoulas V, Metsios G, Pace A, John H, Treharne G, Banks M, et al.Hypertension in rheumatoid arthritis. Rheumatology. 2008;47:1286-98.
47. Al-Herz A, Ensworth S, Shojania K, Esdaile J. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol. 2003;30:493-6. (Pubitemid 36301940)
48. Budman D, Steinberg A. Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med. 1976;136:1003-7.
49. • Sabio J, Vargas-Hitos J, Navarrete-Navarrete N, Mediavilla J, Jimenez-Jaimez J, Diaz-Chamarro A, et al. Prevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosus. J Rheumatol. 2011;38(6):1026-32. This study directly assessed the prevalence of hypertension in female SLE patients and demonstrated that it is 2-4 times greater in age-matched healthy females.
50. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension. 2001;37:1075-82. (Pubitemid 32304007)
51. Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, et al. Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int Suppl. 2008;111:S55-9.
52. •• Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson R, et al. Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt-sensitive hypertension. Am J Physiol Ren Physiol. 2013;304:289-99. This study provides convincing evidence for HSP70 as a self-antigen that could contibute to the autoimmunity and immune system activation in hypertension.
53. Ishizaka N, Aizawa T, Ohno M, Usui S, Mori I, Tang S, et al. Regulation and localization of HSP70 and HSP25 in the kidney of rats undergoing long-term administration of angiotensin II. Hypertension. 2002;39:122-8. (Pubitemid 34098100)
54. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker R, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells. Nature. 2013;496:513-7.
55. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature. 2013;496(7446):513-7.
56. • Mathis KW, Venegas-Pont M, Masterson C, Wasson K, Ryan MJ. Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive. Am J Physiol Regul Integr Comp Physiol. 2011;301:1281-5. This study shows that salt sensitivity does not contribute to the hypertension in SLE mice.
57. Kristensen B, Andersen P. Autoantibodies in untreated and treated essential hypertension. Acta Med Scand. 1978;203:55-9. (Pubitemid 8265844)
58. Kristensen B, Andersen P, Wiik A. Autoantibodies and vascular events in essential hypertension: a five-year longitudinal study. J Hypertens. 1984;2:19-24. (Pubitemid 14162294)
59. Gudbrandsson T, Hansson L, Herlitz H, Lindholm L, Nilsson LA. Immunological changes in patients with previous malignant essential hypertension. Lancet. 1981;1:406-8. (Pubitemid 11188931)
60. Wenzel K, Haase H, Wallukat G, Derer W, Bartel S, Homuth V, et al. Potential relevance of alpha (1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE. 2008;3:e3742.
61. .• Jahns R, Boivin V, Lohse M. Beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med. 2006;16:20-4. This describes an important role for autoantibodies in cardiovascular disorders. (Pubitemid 43012037)
62. Xia Y, Kellems R. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res. 2013;113:78-87.
63. Dragun D, Muller D, Brasen J, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558-69. (Pubitemid 40204669)
64. • Pons-Estel G, Alarcon G, Scofield L, Reinlib L, Cooper G. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-1. This paper describes the current statistics on patients with SLE.
65. Lawrence R, Helmick C, Arnett F, Deyo R, Felson D, Giannini E, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 2013;41(5):778.
66. Chakravarty E, Bush T, Manzi S, Clarke A, Ward M. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56(6):2092.
67. • Mathis KW, Venegas-Pont M, Masterson C, Stewart N, Wasson K, Ryan MJ. Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus. Hypertension. 2012;59:673-9. This study shows that renal oxidative stress has a causal role in the development of hypertension during SLE.
68. Mathis KW, Venegas-Pont M, Flynn E, Williams J, Maric-Bilkan C, Dwyer T, et al. Hypertension in an experimental model of systemic lupus erythematosus occures independently of the renal nerves. Am J Physiol Regul Integr Comp Physiol. 2013;301:1286-92.
69. Ryan MJ, McLemore GR. Hypertension and impaired vascular function in a femalemousemodel of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2007;292:736-42.
70. • Venegas-Pont M, Manigrasso MB, Grifoni SC, LaMarca BB, Maric C, Racusen LC, et al. Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosus. Hypertension. 2010;56:643-9. This work illustrates the important role of renal cytokines in the pathogensesis of hypertension during SLE.
71. .• Rudofsky UH, Dilwith RL, Roths JB, Lawrence DA, Kelley VE, Magro AM. Differenses in the occurence of hypertension among (NZB x NZW)F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol. 1984;116:107-14. This study demonstrates that mice with SLE have increased systolic pressure and low plasma renin. (Pubitemid 14087098)
72. Venegas-Pont M, Mathis KW, Iliescu R, Ray WH, Glover P, Ryan M. Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2011;301(5):1286-92.
73. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2013;14(9):837-54.
74. Obarzanek E, Proschan M, Vollmer W, Moore T, Sacks F, Appel L, et al. Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension. 2003;42(4):459-67. (Pubitemid 37237339)
75. Mathis KW, Wallace K, Wasson K, Masterson C, Ryan M. T cells promote the progression of hypertension and renal injury during systemic lupus erythematosus. Hypertension. 2012;60:A174.
76. Mathis KW, Wallace K, LaMarca B, Ryan M. Humoral immune system activation promotes the development of hypertension. FASEB J. 2013;27:906.4.
77. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953-60. (Pubitemid 40834939)
78. Stumpf C, Auer C, Yilmaz A, Lewczuk P, Klinghammer L, Schneider M, et al. Serum levels of the Th1 chemoattractant interferon-gamma-inducible protein (IP) 10 are elevated in patients with essential hypertension. Hypertens Res. 2011;34:484-8.
79. Jong-Chan Y*, Hee Tae Y*, Beom JL, Myoung JK, Jino L, Dong- Yeop C, et al. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62:126-33.
80. Hughson MD, Gobe GC, Hoy WE, Manning RD, Douglas-Denton R, Bertram JF. Associations of glomerular number and birth weight with clinicopathological features of African Americans and whites. Am J Kidney Dis. 2008;52:18-28. (Pubitemid 351853270)
81. Heptinstall RH. Renal biopsies in hypertension. Br Heart J. 1954;16:133-41.
82. Pockley AG, De Faire U, Kiessling R, Lemne C, Thulin T, Frostegård J. Circulating heat shock protein and heat shock protein antibody levels in established hypertension. J Hypertens. 2002;20:1815-29.
83. Kunes J, Poirier M, Tremblay J, Hamet P. Expression of HSP70 gene in lymphocytes from normotensive and hypertensive humans. Acta Physiol Scand. 1992;146:307-11.
84. Lefkos N, Boura P, Boudonas G, Zacharioudaki E, Efthimiadis A, Tsougas M, et al. Immunopathogenic mechanisms in hypertension. Am J Hypertens. 1995;8:1141-5.
85. Kronbichler A, Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Med. 2013;11:95.
86. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433-42.